Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2018-10-25 Capital/Financing Update
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos and AbbVie restructure CF collaboration
Capital/Financing Update Classification · 95% confidence The document is a press release dated October 24, 2018, announcing a restructuring of a collaboration agreement between Galapagos and AbbVie concerning cystic fibrosis (CF) programs. It details financial considerations (upfront payment, milestones, royalties) and rights transfer. This type of announcement, which details significant business transactions, financing terms, or strategic shifts, fits best under 'Capital/Financing Update' (CAP) if it involves raising capital or major debt restructuring, or 'Regulatory Filings' (RNS) if it's a general market disclosure. Since it specifically details a major financial transaction involving payments and future milestones related to asset transfer, it strongly aligns with the 'Capital/Financing Update' (CAP) category, which covers fundraising, financing activities, or capital structure changes, as the restructuring involves significant financial components and asset valuation changes. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Given the focus on the financial terms of the deal, CAP is the most specific fit over the general RNS fallback.
2018-10-25 English
Topline interim results of FALCON trial Part 1 in CF
Earnings Release Classification · 95% confidence The document is a press release dated October 24, 2018, announcing 'topline interim results' of a clinical trial (FALCON trial) for a novel combination treatment in cystic fibrosis (CF). It details preliminary safety, PK, and efficacy data (sweat chloride decrease, ppFEV1 increase). This structure—announcing key periodic results outside of a full annual or quarterly report filing—is characteristic of an Earnings Release (ER) or a specific clinical/research update. Since it focuses purely on announcing the results of a specific operational/research milestone rather than comprehensive financial performance for a period (which would be IR or 10-K), and it is a formal announcement from a listed company, it fits best under the Earnings Release category, which often includes operational highlights alongside financial snippets, or is used for major non-financial operational news releases. Given the options, 'ER' (Earnings Release) is the closest fit for a press release announcing key operational/trial results, even if it's not strictly a quarterly financial report. It is a direct announcement of performance metrics. It is not a full report (10-K, IR), a presentation (IP), or a transcript (CT). FY 2018
2018-10-25 English
Topline interim results of FALCON trial Part 1 in CF
Earnings Release Classification · 95% confidence The document is a press release dated October 24, 2018, announcing 'tussentijdse resultaten' (interim results) from Part 1 of the FALCON study concerning cystic fibrosis treatments. It details preliminary safety, PK, and efficacy data (changes in sweat chloride and ppFEV1%). This structure—an initial announcement of period-specific financial or clinical results, often released before a comprehensive quarterly report—aligns best with an Earnings Release (ER) or, given the clinical trial focus, potentially an Interim Report (IR) if it were a comprehensive financial document. However, since it is a specific announcement of clinical trial results and key data points, and not a full financial report (like a 10-Q or 10-K), it functions as an initial results announcement. In the context of biotech/pharma, these clinical updates often serve the same purpose as an ER for general market awareness. Since the document is a press release announcing key results and not a comprehensive 'Interim Report' (IR) or a full 'Annual Report' (10-K), and it is not a transcript (CT) or a presentation (IP), 'ER' (Earnings Release) is the most appropriate classification for a material results announcement. Q4 2018
2018-10-25 English
Hallmark third quarter 2018 and Annual R&D Update at Galapagos
Earnings Release Classification · 100% confidence The document is an official announcement from Galapagos NV regarding their financial results for the first nine months of 2018. It contains key financial highlights (revenue, operating loss, net loss, cash position) and provides a summary of operational progress. Crucially, the text explicitly states that these results are 'not-audited' and that the full, detailed quarterly report is available separately on their website, which aligns with the definition of an Earnings Release (ER) rather than a full Interim Report (IR). 9M 2018
2018-10-25 English
Hallmark third quarter 2018 and Annual R&D Update at Galapagos
Earnings Release Classification · 100% confidence The document is an earnings release (ER) from Galapagos NV. It provides a summary of financial results for the third quarter of 2018, including key performance indicators like revenues, operating loss, and cash position. While it mentions that a more detailed report is available on their website, the document itself contains the core financial highlights, management commentary, and outlook, which is characteristic of an Earnings Release. It does not meet the criteria for an RPA because it provides substantive financial data rather than just announcing the availability of a report. 9M 2018
2018-10-25 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Galapagos NV, pursuant to SEC rules. It includes a press release as Exhibit 99.1 dated October 24, 2018. The document length is 2674 characters, which is relatively short and mainly serves to submit the press release to the SEC. There is no substantive financial data or detailed report content within this filing itself. According to the 'Menu vs Meal' rule, such a document that primarily attaches or references a press release or report without containing the report itself should be classified as a Regulatory Filing (RNS).
2018-10-25 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.